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With the generous support of an unrestricted educa- 
tional grant from Rh6ne-Poulenc Rorer Foundation, 
a group of international experts from 13 countries 
gathered in Paris on 3 December 1998 to compare 
notes and examine the feasibility of various approaches 
by which the continued alarming increase and spread 
of drug-resistant respiratory pathogens, primarily 
Streptococcus pneumoniae, could be reduced and, hope- 
fully, brought to a halt. Conveners of the meeting were 
Drs Claude Carbon, Herminia de Lencastre, Karl 
Ekdahl, Karl Kristinsson, and Alexander Tornasz. 
Alarm over the increasing frequency and geo- 
graphic spread of drug-resistant pathogens has often 
been voiced, both at professional meetings and in the 
public media. Of  particular concern is the increase in 
multiply-resistant pathogens, which raises the specter of 
bacterial disease untreatable by traditional antimicrobial 
therapy. Among these are diseases for which children of 
young age are at particularly high risk, namely, diseases 
caused by S. pneumoniae. This microbe is a major cause 
of a variety of potentially life-threatening community- 
acquired diseases, both in children and in adults. 
Pneumococci are the causative agents of a large portion 
of the several million annual cases of otitis media, 
which, in many countries, is the single most frequent 
cause of visits to doctors’ offices and which is the most 
frequent reason for the prescription and use of anti- 
microbial agents. 
The nasopharyngeal flora of young children is 
known to be an important, if not the main, ecological 
reservoir of S. pneumonim (along with other respiratory 
pathogens such as Haemophilus injuenzae and hforaxella 
catarrh&). In addition, the ovenvhelining majority of 
all drug-resistant pneumococci were shown to express 
only a limited number (5-7) of all capsular types from 
the large genetic repertoire (90 different polysaccharide 
structures) of S. pneumonie. These few capsular types 
happen to represent the so-called ‘pediatric types’: 
capsular polysaccharides against which the immature 
immune system of children has difficulty in mounting 
an antibody response. Thus, children are not only 
primary targets of pneumococcal disease but are the 
most important non-symptomatic carriers of anti- 
biotic-resistant strains of S. pneumoniae as well. 
Social trends often lead to the recruitment of an 
increasing proportion of pre-school children into day- 
care centers and kindergartens, thus bringing together 
into close physical proximity the very age group in 
which immunologic status, behavior, frequent viral 
respiratory diseases and the frequent use of antimicro- 
bials virtually optimize condtions for the transmission 
and increase of drug-resistant pathogens. Several studies 
have demonstrated that attendance in day-care centers 
more than doubles the risk of carriage of drug-resistant 
strains of pneumococci. Recent studies have also begun 
to show that the likely source of drug-resistant strains 
causing infections in hospitalized patients is children 
attending day-care in the same locality. 
It was with this background that the Paris Work- 
shop brought together a group of international experts 
to review relevant information on various aspects of 
drug-resistant S. pneumaniue, with particular eniphasis 
on experiences unique to various countries. Presen- 
tations included: mscussion of the relationship between 
antibiotic usage and the incidence of drug resistance 
based primarily on studies performed in Finland; 
evaluation of the effectiveness of communication tech- 
niques in reaching both prescribers and users of 
antibiotics in Iceland, with the purpose of reducing 
antibiotic use; description of the Swedish initiative in 
testing infection control measures in controlling the 
spread of resistant pneumococci in the community and 
studies performed in France on the impact of antibiotic 
dosing and treatment duration on the rate of carriage 
of resistant pneumococci. An update on the design of 
conjugate vaccines and the impact of their use on the 
rate of carriage of S. pneirmoriine in Israel was described, 
followed by the report of a large-scale study involving 
over 2000 children and 12 day-care centers in Lisbon, 
Portugal, in which molecular typing techniques were 
used to characterize drug-resistant strains of pneumo- 
cocci. A review of the impact of antibiotic resistance 
on treatment of pneumococcal diseases, description of 
in vitro and epidemiologic models for the study of 
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mixed populations of resistant and susceptible pneumo- 
cocci, and an update on the molecular biology of drug- 
resistant genes and epidemic clones completed the 
Workshop. 
The presentations served as starting points for 
discussion and comments by a group of invited 
participants. The ultimate purpose of the meeting was 
to serve as a springboard for launching a coordinated, 
multinational effort in Europe, with the aim of putting 
a brake on the spread of antibiotic-resistant strains of 
pneumococci and pneumococcal disease. A unique 
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feature of this initiative is that it targets the ecological 
reservoir of the resistant bacteria, which is the 
pneumococcal flora colonizing the nasopharynx of 
chddren. 
The conveners and participants of the Workshop 
express their gratitude to Dr Yves Champey, President 
of Rh8ne Poulenc Rorer Foundation, and to Dr Ivan 
Brumpt and his staff, for all their contributions which 
made the Paris Workshop possible. 
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